A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- Registration Number
- NCT02163694
- Lead Sponsor
- AbbVie
- Brief Summary
The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2 (BRCA1; BRCA2) mutation in Human Epidermal Growth Factor Receptor 2 (HER2)-negative metastatic or locally advanced unresectable breast cancer. The secondary objectives of the study are to assess overall survival (OS), clinical benefit rate (CBR) through the end of Week 24, objective response rate (ORR) and PFS on subsequent therapy (PFS2) in participants treated with veliparib in combination with C/P versus placebo in combination with C/P.
- Detailed Description
This is a Phase 3, randomized, double-blind, multinational, multicenter study to evaluate the efficacy and tolerability of veliparib in combination with C/P compared to placebo in combination with C/P in participants with a BRCA1 or BRCA2 mutation, as documented by the Sponsor core laboratory, with HER2-negative metastatic or locally advanced unresectable breast cancer who received no more than 2 prior lines of cytotoxic therapy for metastatic disease. For the purposes of eligibility, HER2-negative status was based on the most recent tumor biopsy. Participants were randomized in a 2:1 ratio, with a total of approximately 500 participants planned to be randomized. Veliparib 120 mg/placebo twice a day (BID) was dosed Days -2 through 5 with carboplatin target area under the concentration-time curve (AUC) 6 administered on Day 1 and paclitaxel 80 mg/m2 administered weekly on Days 1, 8, and 15 of each 21-day cycle.
Safety and efficacy data through the prespecified primary analysis cutoff date of 05 April 2019 are included in the interim analysis.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 509
- Histologically or cytologically confirmed breast cancer that is either locally advanced or metastatic. Locally advanced breast cancer must not be amenable to surgical resection or radiation with curative intent.
- Suspected deleterious or deleterious Breast Cancer Gene 1 (BRCA1) and/or Breast Cancer Gene 2 (BRCA2) germline mutation.
- Breast cancer must be Human Epidermal Growth Factor Receptor 2 (HER2)-negative.
- Measurable or non-measurable (but radiologically evaluable) disease per Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1 on computed tomography (CT) scan (within 28 days of randomization) with at least one lesion outside previously irradiated areas.
- Eastern Cooperative Oncology Group (ECOG) Performance status of 0 to 2.
- Adequate hematologic, renal, and hepatic function (within 28 days of randomization).
-
More than two prior lines of cytotoxic chemotherapy (e.g., gemcitabine, doxorubicin, capecitabine) for metastatic disease.
- Regimens received in the adjuvant/neoadjuvant setting or for locally advanced breast cancer within the past 6 months will also be considered toward the maximum of 2 prior lines of therapy. Adjuvant/neoadjuvant chemotherapy for one cancer event will count as one prior line of therapy, if received within the past 6 months.
- Previous treatments with hormonal therapy (tamoxifen, aromatase inhibitors) and signal transduction agents (e.g., erlotinib, gefitinib, everolimus, bevacizumab) are allowed and are not counted towards the prior line of therapy.
-
Progressed or recurred within 12 months of completing platinum therapy or received > 1 prior line of platinum therapy for breast cancer in any setting (adjuvant, neoadjuvant, or metastatic).
-
Prior therapy with Poly(ADP-ribose)-Polymerase (PARP) inhibitors.
-
Prior taxane therapy administered for the treatment of metastatic breast cancer with the below exceptions.
- Prior taxane therapy for metastatic breast cancer is allowed if the patient received ≤ 1 full cycle (i.e., therapy discontinued within 4 weeks for subjects receiving weekly paclitaxel or Abraxane; therapy discontinued within 3 weeks for subjects receiving paclitaxel or docetaxel every 3 weeks) in the absence of progression or if taxane therapy for metastatic disease was > 12 months prior to Cycle 1 Day-2 (C1D-2).
- Use of taxanes as adjuvant therapy or to treat locally advanced disease is permitted, if given more than 6 months prior to C1D-2
-
Known history of allergic reaction to cremophor-paclitaxel, carboplatin, Azo-Colourant Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.
-
Active CNS metastases or leptomeningeal disease.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Veliparib Placebo with Carboplatin and Paclitaxel Veliparib Placebo Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle. Veliparib Placebo with Carboplatin and Paclitaxel Carboplatin Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle. Veliparib Placebo with Carboplatin and Paclitaxel Paclitaxel Placebo capsules for veliparib (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle. Veliparib with Carboplatin and Paclitaxel Veliparib Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle. Veliparib with Carboplatin and Paclitaxel Carboplatin Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle. Veliparib with Carboplatin and Paclitaxel Paclitaxel Veliparib capsules (120 mg) administered by mouth twice daily (BID) on Days -2 through 5 of a 21-day cycle. Carboplatin administered intravenously over approximately 15 to 30 minutes at AUC 6 mg/ml/min immediately following paclitaxel infusion on Day 1 of every cycle. Paclitaxel administered intravenously over approximately 1 hour at a dose of 80 mg/m² on Days 1, 8, and 15 of every cycle.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) From randomization until the primary analysis data cut-off date of 05 April 2019; the median duration of follow-up was 35.5 months Time to PFS is defined as the number of days from the date the participant was randomized to the date the participant experiences radiographic disease progression (as determined by the investigators), or to the date of death (all causes of mortality) if disease progression is not reached. All events of disease progression occurring on or before the Primary Analysis Cutoff date of 05 April 2019 were to be included, regardless of whether the event occurred while the participant was still taking study drug or had previously discontinued study drug. PFS was estimated for each treatment group using Kaplan-Meier methodology.
- Secondary Outcome Measures
Name Time Method Clinical Benefit Rate (CBR) Through the end of Week 24 The clinical benefit rate (CBR) for each treatment group was to be obtained from a time-to-event analysis of radiographic disease progression per the investigator. CBR is defined as the progression-free rate at 24 weeks (168 days), estimated for each treatment arm using Kaplan Meier methodology. All events of disease progression in the primary progression free survival analysis database were to be included, regardless of whether the event occurred while the participant was still taking, or had previously discontinued, study drug. If the participant had not yet progressed then their data was to be censored at the date of the last evaluable disease progression assessment. Participants without post-baseline assessments were to be censored at the date of randomization.
The final analysis of CBR will occur when the pre-specified number of Overall Survival events have occurred in the ITT population, per the fixed sequence testing procedure.Overall Survival (OS) Approximately 8 years from randomization Time to death (overall survival) is defined as the number of days from the date the participant was randomized to the date of the participant's death. All events of death which occur up to the analysis cutoff date are to be included, regardless of whether the event occurred while the participant was still taking study drug or after the participant discontinued study drug. If a participant has not died, the data for the participant is to be censored at the date last known to be alive or at the analysis cutoff date if that is earlier.
The final analysis of OS will occur when the pre-specified number of events has occurred in the ITT population.Objective Response Rate (ORR) Approximately 8 years from randomization The objective response rate (ORR) is calculated as the percentage of participants who have a confirmed partial response (PR) or complete response (CR) based on assessment by the investigators per Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1. All participants who had at least one measurable lesion at baseline were to be included in the ORR calculation.
The final analysis of ORR will occur when the pre-specified number of Overall Survival events have occurred in the ITT population, per the fixed sequence testing procedure.Progression-Free Survival on Subsequent Therapy (PFS2) Approximately 8 years from randomization PFS2 is defined as the number of days from the date of randomization to the time of disease progression on subsequent therapy or death from any cause. The distribution of PFS2 was to be estimated for each treatment group using Kaplan-Meier methodology.
The final analysis of PFS2 will occur when the pre-specified number of Overall Survival events have occurred in the ITT population, per the fixed sequence testing procedure.
Trial Locations
- Locations (219)
University of Illinois - Chicago /ID# 127576
🇺🇸Chicago, Illinois, United States
Allegheny General Hospital /ID# 135094
🇺🇸Pittsburgh, Pennsylvania, United States
University of Pittsburgh MC /ID# 125005
🇺🇸Pittsburgh, Pennsylvania, United States
University of Texas MD Anderson Cancer Center /ID# 125353
🇺🇸Houston, Texas, United States
Swedish Medical Center /ID# 125021
🇺🇸Seattle, Washington, United States
Swedish Cancer Insititute - Ballard /ID# 131548
🇺🇸Seattle, Washington, United States
Duplicate_AZ St-Jan Brugge-Oostende AV /ID# 124975
🇧🇪Brugge, West-Vlaanderen, Belgium
CHU UCL Namur - Sainte Elisabeth /ID# 124979
🇧🇪Namur, Belgium
Centro Hospitalar Universitário do Algarve, EPE - Hospital Faro /ID# 125298
🇵🇹Faro, Portugal
Duke Cancer Center /ID# 124999
🇺🇸Durham, North Carolina, United States
Hollywood Private Hospital /ID# 124843
🇦🇺Nedlands, Western Australia, Australia
IRCCS Ospedale Sacro Cuore Don Calabria /ID# 125262
🇮🇹Negrar, Verona, Italy
Henry Ford Health System /ID# 134497
🇺🇸Detroit, Michigan, United States
Instituto Nacional del Cancer /ID# 129343
🇨🇱Santiago, Chile
State Institution Republican Scientific Practical Center of Oncology and Medical /ID# 125223
🇧🇾Minsk, Belarus
Norwalk Hospital /ID# 133509
🇺🇸Norwalk, Connecticut, United States
Ordensklinikum Linz GmbH Elisabethinen /ID# 126185
🇦🇹Linz, Oberoesterreich, Austria
Duplicate_Mogilev Reg Clin Oncology Dis /ID# 137728
🇧🇾Mogilev, Belarus
Duplicate_Jewish General Hospital /ID# 124880
🇨🇦Montreal, Quebec, Canada
Duplicate_CHUQ-Hospital St. Sacrement /ID# 124881
🇨🇦Quebec City, Quebec, Canada
Clinica Pergamino /ID# 127158
🇦🇷Pergamino, Buenos Aires, Argentina
Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz /ID# 124911
🇭🇺Szolnok, Hungary
The Chaim Sheba Medical Center /ID# 124918
🇮🇱Ramat Gan, Tel-Aviv, Israel
Kaplan Medical Center /ID# 124914
🇮🇱Rehovot, Israel
Centro de Estudios Clínicos Especializados /ID# 128680
🇲🇽Mérida, Yucatan, Mexico
The Royal Melbourne Hospital /ID# 124846
🇦🇺Parkville, Victoria, Australia
Hospital Pablo Tobon Uribe /ID# 126657
🇨🇴Medellín, Antioquia, Colombia
Banner MD Anderson Cancer Ctr /ID# 125011
🇺🇸Gilbert, Arizona, United States
University of Arkansas for Medical Sciences /ID# 124992
🇺🇸Little Rock, Arkansas, United States
Rutgers Cancer Institute of New Jersey /ID# 125017
🇺🇸New Brunswick, New Jersey, United States
Centro Oncologico Riojano Integral /ID# 127938
🇦🇷La Rioja, Argentina
Landeskrankenhaus Salzburg-Universitätsklinikum der PMU (LKH) /ID# 126449
🇦🇹Salzburg, Austria
Vitebsk Regional Clinical Oncology Dispensary /ID# 125219
🇧🇾Vitebsk, Belarus
Institut de Cancérologie de l'Ouest René Gauducheau /ID# 137726
🇫🇷St Herblain CEDEX, Loire-Atlantique, France
Pecsi Tudomanyegyetem Klinikai Kozpont /ID# 125259
🇭🇺Pecs, Hungary
Rambam Health Care Campus /ID# 124916
🇮🇱Haifa, Israel
Univ of Mississippi Med Ctr,US /ID# 131352
🇺🇸Jackson, Mississippi, United States
Nebraska Hematology Oncology /ID# 132711
🇺🇸Lincoln, Nebraska, United States
Instituto de Oncoloia de Rosario /ID# 127157
🇦🇷Rosario, Santa Fe, Argentina
COIBA Centro de Oncologia e Investigacion de Buenos Aires /ID# 124839
🇦🇷Berazategui, Buenos Aires, Argentina
University of Vermont Medical Center /ID# 125350
🇺🇸Burlington, Vermont, United States
Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE /ID# 126510
🇵🇹Vila Nova De Gaia, Porto, Portugal
Universitair Ziekenhuis Leuven /ID# 124980
🇧🇪Leuven, Vlaams-Brabant, Belgium
Administradora del Country_S.A-Clinica Del Country /ID# 125255
🇨🇴Bogota, Cundinamarca, Colombia
Centro Medico Imbanaco de Cali /ID# 126656
🇨🇴Cali, Colombia
Assaf Harofeh Medical Center /ID# 124915
🇮🇱Be'Er Ya'Akov, Israel
Instituto Nacional de Cancerología INCAN /ID# 128676
🇲🇽Ciudad de Mexico, Mexico
Haukeland University Hospital /ID# 150177
🇳🇴Bergen, Hordaland, Norway
Wojewodzki Szpital Zespolony /ID# 126998
🇵🇱Elblag, Warminsko-mazurskie, Poland
IPO Porto FG, EPE /ID# 125297
🇵🇹Porto, Portugal
Sverdlovsk Regional Oncology Dispensary /ID# 130950
🇷🇺Yekaterinburg, Sverdlovskaya Oblast, Russian Federation
Altay Regional Oncological Dispesary /ID# 127160
🇷🇺Barnaul, Russian Federation
Johns Hopkins Singapore IMC /ID# 125316
🇸🇬Singapore, Singapore
Royal Hobart Hospital /ID# 124849
🇦🇺Hobart, Tasmania, Australia
CHUM - Notre-Dame Hospital /ID# 124879
🇨🇦Montréal, Quebec, Canada
Hospital Clinico Vina del Mar /ID# 130100
🇨🇱Vina Del Mar, Valparaíso, Chile
Duplicate_Saratov State Medical University n.s. Chernyshevskiy /ID# 139395
🇷🇺Saratov, Russian Federation
LLC BioEq Ltd. /ID# 134529
🇷🇺St. Petersburg, Russian Federation
Municipal Non-Profit Enterprise City Clinical Hospital No.4 of Dnipro City Counc /ID# 124968
🇺🇦Dnipro, Ukraine
ME Kryviy Rih Oncology Dispensary /ID# 129806
🇺🇦Кривий Ріг, Ukraine
Netcare Oncology Intervent Ctr /ID# 125320
🇿🇦Cape Town, Western Cape, South Africa
Hospital Univ San Ignacio /ID# 126655
🇨🇴Bogota, Cundinamarca, Colombia
East Tallinn Central Hospital /ID# 126475
🇪🇪Kesklinna Linnaosa, Harjumaa, Estonia
Duplicate_Tampere University Hospital /ID# 124898
🇫🇮Tampere, Finland
Tel Aviv Sourasky Medical Center /ID# 130276
🇮🇱Tel Aviv-Yafo, Tel-Aviv, Israel
Gastroenterology Institute, Division of Medicine /ID# 124919
🇮🇱Jerusalem, Israel
Hospital of Lithuanian University of Health Sciences Kaunas Clinics /ID# 125266
🇱🇹Kaunas, Lithuania
Erasmus Medisch Centrum /ID# 124935
🇳🇱Rotterdam, Zuid-Holland, Netherlands
Maastricht Universitair Medisch Centrum /ID# 129068
🇳🇱Maastricht, Netherlands
Centrum Onkologii Lukaszczyka /ID# 124938
🇵🇱Bydgoszcz, Kujawsko-pomorskie, Poland
Duplicate_lnstitutul Oncologic Prof Dr Alexandru Trestioreanu /ID# 124943
🇷🇴Bucharest, Romania
Oncomed SRL /ID# 127598
🇷🇴Timisoara, Romania
Duplicate_archangel Clinical Oncology /ID# 126031
🇷🇺Arkhangelsk, Russian Federation
Belgorod Oncology Dispensary /ID# 129315
🇷🇺Belgorod, Russian Federation
Pauls Stradins Clinical University Hospital /ID# 125264
🇱🇻Riga, Latvia
Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopern /ID# 126999
🇵🇱Lodz, Lodzkie, Poland
Ad-Vance Medical Research, LLC /ID# 126043
🇵🇷Ponce, Puerto Rico
Siberian State Medical University /ID# 127161
🇷🇺Tomsk, Russian Federation
Lviv Oncological Regional Therapeutical and Diagnostic Centre /ID# 124974
🇺🇦Lviv, Ukraine
Poltava Regional Clinical Oncology Centre of Poltava Regional Council /ID# 124969
🇺🇦Poltava, Ukraine
Zaporizhzhia Med. Academy MOH /ID# 129800
🇺🇦Zaporizhia, Ukraine
Universitair Medisch Centrum Groningen /ID# 129069
🇳🇱Groningen, Netherlands
Wojewodzki Szpital Specjalistyczny /ID# 127258
🇵🇱Wroclaw, Dolnoslaskie, Poland
Centro Hospitalar Universitário de Lisboa Norte, EPE - Hospital de Santa Maria /ID# 125299
🇵🇹Lisboa, Portugal
S.C. Centrul de Oncologie Sf. Nectarie S.R.L. /ID# 124948
🇷🇴Craiova, Dolj, Romania
Regional Oncology Dispensary /ID# 125936
🇷🇺Kursk, Tatarstan, Respublika, Russian Federation
University of Free State, Universitas Annex (National Hospital Grounds) /ID# 128499
🇿🇦Bloemfontein, Free State, South Africa
Hull University Teaching Hospitals NHS Trust /ID# 133030
🇬🇧Hull, East Riding Of Yorkshire, United Kingdom
Donetsk Regional Antitumor Ctr /ID# 124970
🇺🇦Donetsk, Ukraine
Saint Joseph Hospital /ID# 131768
🇺🇸Denver, Colorado, United States
City of Hope /ID# 127117
🇺🇸Duarte, California, United States
Moores Cancer Center at UC San Diego /ID# 124991
🇺🇸La Jolla, California, United States
Hematology and Oncology Assoc /ID# 130058
🇺🇸Newport Beach, California, United States
Icri /Id# 128520
🇺🇸Whittier, California, United States
Lynn Cancer Institute, Boca /ID# 125013
🇺🇸Boca Raton, Florida, United States
Sacred Heart Hospital /ID# 128279
🇺🇸Pensacola, Florida, United States
Holy Cross Hospital /ID# 125012
🇺🇸Fort Lauderdale, Florida, United States
Florida Cancer Specialists - East /ID# 125007
🇺🇸West Palm Beach, Florida, United States
Emory Midtown Infectious Disease Clinic /ID# 133192
🇺🇸Atlanta, Georgia, United States
The Cancer Ctr at DeKalb Med C /ID# 125024
🇺🇸Decatur, Georgia, United States
NorthShore University HealthSystem /ID# 124996
🇺🇸Evanston, Illinois, United States
Midwestern Regional CTC /ID# 124986
🇺🇸Zion, Illinois, United States
Baystate Medical Center /ID# 139461
🇺🇸Springfield, Massachusetts, United States
McFarland Clinic, PC /ID# 129904
🇺🇸Ames, Iowa, United States
Johns Hopkins University /ID# 125015
🇺🇸Baltimore, Maryland, United States
Spectrum Health Medical Group /ID# 133568
🇺🇸Grand Rapids, Michigan, United States
UMass Chan Medical School /ID# 129067
🇺🇸Worcester, Massachusetts, United States
Spectrum Health Medical Group /ID# 148471
🇺🇸Grand Rapids, Michigan, United States
William Beaumont Hospital /ID# 125019
🇺🇸Royal Oak, Michigan, United States
Washington University-School of Medicine /ID# 127575
🇺🇸Saint Louis, Missouri, United States
University of New Mexico /ID# 125349
🇺🇸Albuquerque, New Mexico, United States
Beth Israel Medical Center /ID# 125001
🇺🇸New York, New York, United States
Mount Sinai St. Luke's /ID# 125003
🇺🇸New York, New York, United States
Oregon Health and Science University /ID# 134229
🇺🇸Portland, Oregon, United States
University of Toledo /ID# 134849
🇺🇸Toledo, Ohio, United States
The Ohio State University /ID# 125022
🇺🇸Columbus, Ohio, United States
Lehigh Valley Health Network /ID# 130059
🇺🇸Allentown, Pennsylvania, United States
Lehigh Valley Hosp/Muhlenberg /ID# 130277
🇺🇸Bethlehem, Pennsylvania, United States
Penn State University and Milton S. Hershey Medical Center /ID# 124997
🇺🇸Hershey, Pennsylvania, United States
Texas Health Physicians Group /ID# 137740
🇺🇸Arlington, Texas, United States
University of Texas Southwestern Medical Center /ID# 124989
🇺🇸Dallas, Texas, United States
Swedish Cancer Institute - Issaquah /ID# 131534
🇺🇸Issaquah, Washington, United States
Swedish Cancer Institute - Edmonds /ID# 131549
🇺🇸Seattle, Washington, United States
Northwest Medical Specialties - Tacoma /ID# 125344
🇺🇸Tacoma, Washington, United States
St George Hospital /ID# 129416
🇦🇺Kogarah, New South Wales, Australia
Duplicate_The Prince of Wales Hospital /ID# 124845
🇦🇺Randwick, New South Wales, Australia
Southern Medical Day Care Centre /ID# 124844
🇦🇺Wollongong, New South Wales, Australia
Townsville University Hospital /ID# 126731
🇦🇺Douglas, Queensland, Australia
Duplicate_Flinders Centre for Innovation /ID# 127535
🇦🇺Bedford Park, South Australia, Australia
Medizinische Universitaet Graz /ID# 126450
🇦🇹Graz, Steiermark, Austria
Medizinische Universitaet Wien /ID# 126184
🇦🇹Vienna, Wien, Austria
Bobruysk Interdistrict Onco. /ID# 137729
🇧🇾Bobruisk, Belarus
Universitair Ziekenhuis Antwerpen /ID# 124977
🇧🇪Edegem, Antwerpen, Belgium
UCL Saint-Luc /ID# 124976
🇧🇪Woluwe-Saint-Lambert, Bruxelles-Capitale, Belgium
Grand Hôpital de Charleroi /ID# 124981
🇧🇪Charleroi, Hainaut, Belgium
ZNA Middelheim /ID# 124978
🇧🇪Antwerp, Belgium
Duplicate_Sunnybrook Health Sciences Ctr /ID# 124882
🇨🇦Toronto, Ontario, Canada
Hospital Clinico Vina del Mar /ID# 148502
🇨🇱Vina Del Mar, Valparaíso, Chile
Instituto Medico de Alta Tecnologia Oncomédica S.A /ID# 129211
🇨🇴Monteria, Cordoba, Colombia
ICOS - Inst Clinic Oncology /ID# 125236
🇨🇱Temuco, Chile
Duplicate_FN Hradec Kralove /ID# 127080
🇨🇿Hradec Kralove, Czechia
Docrates Cancer Center /ID# 124896
🇫🇮Helsinki, Finland
Fakultni nemocnice Olomouc /ID# 124885
🇨🇿Olomouc, Czechia
Fakultni Nemocnice Brno /ID# 128176
🇨🇿Brno, Czechia
Masarykuv onkologicky ustav /ID# 124886
🇨🇿Brno, Czechia
Vseobecna fakultni nemocnice v Praze /ID# 124887
🇨🇿Praha, Czechia
Rigshospitalet /ID# 124891
🇩🇰Copenhagen Ø, Hovedstaden, Denmark
Sygehus Lillebælt, Vejle /ID# 124892
🇩🇰Vejle, Syddanmark, Denmark
Duplicate_Helsinki Univ Central Hospital /ID# 124897
🇫🇮Helsinki, Finland
Vaasa Central Hospital /ID# 132548
🇫🇮Vaasa, Finland
Institut Paoli-Calmettes /ID# 124903
🇫🇷Marseille, Bouches-du-Rhone, France
Institut Curie /ID# 124902
🇫🇷Paris CEDEX 05, Ile-de-France, France
Universitaetsklinik Heidelberg /ID# 126664
🇩🇪Heidelberg, Baden-Wuerttemberg, Germany
Universitaetsklinimum Tuebingen /ID# 129968
🇩🇪Tubingen, Baden-Wuerttemberg, Germany
Universitaetsklinikum Koeln /ID# 126905
🇩🇪Köln, Nordrhein-Westfalen, Germany
Universitaetsklinikum Ulm /ID# 135230
🇩🇪Ulm, Baden-Wuerttemberg, Germany
Universitaetsklinikum Carl Gustav Carus an der TU Dresden /ID# 127180
🇩🇪Dresden, Germany
Institut Curie - site CLCC René Huguenin /ID# 124904
🇫🇷Saint-cloud, France
Semmelweis Egyetem /ID# 132485
🇭🇺Budapest, Hungary
Sana Klinikum Offenbach /ID# 126733
🇩🇪Offenbach am Main, Germany
Klinikum rechts der Isar - Technische Universitaet Muenchen /ID# 125256
🇩🇪Munich, Germany
Duplicate_Zala Megyei Korhaz /ID# 131341
🇭🇺Zalaegerszeg, Hungary
Duplicate_Soroka University Medical Center /ID# 124917
🇮🇱Be'er Sheva, Israel
Shaare Zedek Medical Center /ID# 130275
🇮🇱Jerusalem, Israel
Ospedale San Raffaele IRCCS /ID# 125261
🇮🇹Milan, Lombardia, Italy
IEO -Istituto Europeo di Oncologia /ID# 125260
🇮🇹Milan, Milano, Italy
Centro di Riferimento Oncologico /ID# 126738
🇮🇹Aviano, Italy
National Cancer Center /ID# 125602
🇰🇷Goyang, Gyeonggido, Korea, Republic of
Grande Ospedale Metropolitano Bianchi Melacrino Morelli /ID# 125263
🇮🇹Reggio Calabria, Italy
Yonsei University Health System Severance Hospital /ID# 125599
🇰🇷Seoul, Seoul Teugbyeolsi, Korea, Republic of
Korea University Anam Hospital /ID# 128968
🇰🇷Seoul, Korea, Republic of
Asan Medical Center /ID# 125601
🇰🇷Seoul, Korea, Republic of
Riga East Clinical University Hospital /ID# 125265
🇱🇻Riga, Latvia
Samsung Medical Center /ID# 125598
🇰🇷Seoul, Korea, Republic of
National Cancer Institute /ID# 125267
🇱🇹Vilnius, Lithuania
Centro Oncologico de Chihuahua /ID# 128679
🇲🇽Chihuahua, Mexico
MRUK-MED I Spolka z ograniczona odpowiedzialnoscia /ID# 124939
🇵🇱Rzeszow, Podkarpackie, Poland
Unidade Local de Saúde de Matosinhos, EPE /ID# 126511
🇵🇹Matosinhos, Portugal
Centro Hospitalar Universitario de Sao Joao, EPE /ID# 126508
🇵🇹Porto, Portugal
San Juan Municipal Hospital /ID# 124695
🇵🇷San Juan, Puerto Rico
Spitalul Clinic Judetean de Urgenta Cluj -Napoca /ID# 124945
🇷🇴Cluj-Napoca, Romania
National University Hospital /ID# 125315
🇸🇬Singapore, Singapore
Volgograd Regional Clinical Oncology Dispensary /ID# 124952
🇷🇺Volzhsky, Russian Federation
GVI Oncology /ID# 125321
🇿🇦Gqeberha, Eastern Cape, South Africa
Wits Clinical Research Site /ID# 125317
🇿🇦Johannesburg, Gauteng, South Africa
Medical Oncology Ctr Rosebank /ID# 125322
🇿🇦Johannesburg, Gauteng, South Africa
The Oncology Centre /ID# 126104
🇿🇦Durban, Kwazulu-Natal, South Africa
Mary Potter Oncology Centre /ID# 133269
🇿🇦Pretoria, Gauteng, South Africa
Cancercare Outeniqua Oncology Centre /ID# 125319
🇿🇦George, Western Cape, South Africa
Hospital Santa Creu i Sant Pau /ID# 124963
🇪🇸Barcelona, Spain
Hospital Universitario Virgen de la Victoria /ID# 124961
🇪🇸Malaga, Spain
Skane University hospital /ID# 124966
🇸🇪Malmo, Skane Lan, Sweden
Norrlands University hospital /ID# 124967
🇸🇪Umea, Vasterbottens Lan, Sweden
Sahlgrenska University Hospital /ID# 124965
🇸🇪Gothenburg, Vastra Gotalands Lan, Sweden
Duplicate_Karolinska Univ Sjukhuset /ID# 124964
🇸🇪Solna, Sweden
Linkoping University Hospital /ID# 126795
🇸🇪Linkoping, Sweden
Hacettepe University Faculty of Medicine /ID# 125336
🇹🇷Ankara, Turkey
Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 125575
🇨🇳Kaohsiung, Taiwan
Uppsala University Hospital /ID# 126512
🇸🇪Uppsala, Sweden
National Taiwan University Hospital /ID# 125324
🇨🇳Taipei City, Taiwan
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastirma Hastanesi /ID# 125337
🇹🇷Ankara, Turkey
Duplicate_Akdeniz University Medical Fac /ID# 125339
🇹🇷Antalya, Turkey
Bezmi Alem Univ Med Fac Hosp /ID# 127901
🇹🇷Istanbul, Turkey
Istanbul University Istanbul Medical Faculty /ID# 145144
🇹🇷Istanbul, Turkey
Communal non-profit enterprise Regional Center of Oncology /ID# 124972
🇺🇦Kharkiv, Ukraine
University Hospitals Bristol /ID# 128343
🇬🇧Bristol, Bristol, City Of, United Kingdom
Nottingham University Hospitals NHS Trust /ID# 125340
🇬🇧Nottingham, Nottinghamshire, United Kingdom
University Hospitals Birmingham NHS Foundation Trust /ID# 125342
🇬🇧Birmingham, United Kingdom
Hospital General Universitario Gregorio Maranon /ID# 124962
🇪🇸Madrid, Spain
Hospital Universitario HM Sanchinarro /ID# 124960
🇪🇸Madrid, Spain
Seoul National University Hospital /ID# 125600
🇰🇷Seoul, Korea, Republic of
California Cancer Associates for Research & Excellence (cCARE) /ID# 136078
🇺🇸Fresno, California, United States
Mission Cancer Center /ID# 134248
🇺🇸Asheville, North Carolina, United States
Cancer Research Collaboration /ID# 128860
🇺🇸Santa Ana, California, United States
Sandton Oncology Medical Group PTY Ltd /ID# 125323
🇿🇦Johannesburg, Gauteng, South Africa
Univ of Colorado Cancer Center /ID# 124983
🇺🇸Aurora, Colorado, United States
Moffitt Cancer Center /ID# 124990
🇺🇸Tampa, Florida, United States
St. Lukes Cancer Institute /ID# 125023
🇺🇸Kansas City, Missouri, United States
Hospital Clinico Universitario de Valencia /ID# 124959
🇪🇸Valencia, Spain
Related News
Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future ...
- Prev
- 1
- Next